A Phase I/II Double-blind, Randomized, Placebo Controlled, Safety and Immunogenicity, Dose-finding Trial of the Monovalent Zaire Ebola Chimpanzee Adenovirus Vector Candidate Vaccine cAd3-EBOZ in Healthy Adults in Switzerland
Phase of Trial: Phase I/II
Latest Information Update: 29 Mar 2016
At a glance
- Drugs GSK 3390107A (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions
- 22 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 31 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 21 Nov 2014 New trial record